BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to be an efficient tool to cure standard-risk acute lymphocytic leukemia (ALL) in first CR (CR1) but the choice between BU-based or TBI-based conditioning regimens still remains controversial. In this study, the safety and efficacy of BUCY and TBICY myeloablative conditioning regimens in patients undergoing allo-HSCT for ALL in CR1 are evaluated.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital of Southern Medical University
• Collaborators: Guangzhou First People's Hospital; Peking University People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-sen University; Third Affiliated Hospital, Sun Yat-Sen University; Zhujiang Hospital
• Treatments: Busulfan; Cyclophosphamide

Criteria

Inclusion Criteria:

• Standard-risk ALL

• Achieving CR after VILP induction regimen,then receiving three cycles of consolidation therapy

• With negative MRD pre-transplantation

• Undergoing HLA-matched allo-HSCT (related or unrelated)

Exclusion Criteria:

• Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)

• Patients with any conditions not suitable for the trial (investigators' decision)